Delaware
(State or other
jurisdiction ofincorporation or organization)
|
|
32-0463781
(I.R.S.
EmployerIdentification No.)
|
Large
accelerated filer ☐
|
Accelerated
filer ☐
|
Non-accelerated
filer ☐
|
|
Smaller Reporting
Company ☒
|
Emerging growth
company ☒
|
Title of Securities
to be Registered
|
Amount to
be Registered(1)
|
Proposed
Maximum Offering Price Per Share
|
Proposed
Maximum Aggregate Offering Price
|
Amount of
Registration Fee
|
Common Stock,
$0.001 par value
|
1,500,000(2)
|
$4.435
|
$6,652,500(3)
|
$726
|
Exhibit
Number
|
|
Description
|
|
5.1
|
|
Opinion of Legal
Counsel
|
|
10.1
|
|
Monopar Therapeutics Inc. 2016
Stock Incentive Plan (incorporated by reference to Appendix A to
the Registrant’s DEF14A Proxy Statement (file number
001-39070), filed with the SEC on April 29,
2020)
|
|
23.1
|
|
Consent of Independent
Registered Public Accounting Firm
|
|
23.2
|
|
Consent of Legal Counsel (included
in Exhibit 5.1)
|
|
24.1
|
|
Power of Attorney (included on
signature page)
|
|
|
MONOPAR THERAPEUTICS INC.
|
|
|
|
|
|
By:
|
/s/ Chandler D.
Robinson
|
|
|
Chandler D.
Robinson
|
|
|
Chief Executive
Officer and Director
|
Signatures
|
|
Title
|
|
Date
|
/s/ Chandler D.
Robinson
|
|
|
|
November 12,
2020
|
Chandler D.
Robinson
|
|
Chief Executive
Officer and Director (Principal Executive Officer)
|
|
|
/s/ Kim R.
Tsuchimoto
|
|
|
|
November 12,
2020
|
Kim R.
Tsuchimoto
|
|
Chief Financial
Officer (Principal Financial and Accounting Officer)
|
|
|
/s/ Andrew P.
Mazar
|
|
|
|
November
12, 2020
|
Andrew P.
Mazar
|
|
Chief Scientific
Officer and Director
|
|
|
/s/ Christopher M.
Starr
|
|
|
|
November
12, 2020
|
Christopher M.
Starr
|
|
Executive Chairman
of the Board and Director
|
|
|
/s/ Raymond W.
Anderson
|
|
|
|
November
12, 2020
|
Raymond W.
Anderson
|
|
Director
|
|
|
/s/ Michael J.
Brown
|
|
|
|
November
12, 2020
|
Michael J.
Brown
|
|
Director
|
|
|
/s/ Arthur J.
Klausner
|
|
|
|
November
12, 2020
|
Arthur J.
Klausner
|
|
Director
|
|
|
|
|
|
|
|
Exhibit
Number
|
|
Description
|
|
5.1
|
|
|
|
10.1
|
|
Monopar Therapeutics Inc. 2016
Stock Incentive Plan (incorporated by reference to Appendix A to
the Registrant’s
DEF14A Proxy Statement (file number 001-39070), filed with the
SEC on April 29, 2020)
|
|
23.1
|
|
|
|
23.2
|
|
|
|
24.1
|
|
Power of Attorney (included on
signature page)
|
|
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end